We are live on ! Find out more
SGM

Seven Grand Managers Portfolio holdings

AUM $2.48B
1-Year Est. Return 65.09%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+65.09%
3 Year Est. Return
+280.64%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
+$987M
Cap. Flow
+$863M
Cap. Flow %
34.74%
Top 10 Hldgs %
42.35%
Holding
249
New
82
Increased
19
Reduced
17
Closed
73

Top Buys

Rank Stock Value
1
SPCX
SpaceX
SPCX
+$301M
2
DLR icon
Digital Realty Trust
DLR
+$110M
3
NVDA icon
NVIDIA
NVDA
+$93.8M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$72M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$71.5M

Top Sells

Rank Stock Value
1
ECHO
EchoStar
ECHO
+$81.9M
2
TSLA icon
Tesla
TSLA
+$66.9M
3
LRCX icon
Lam Research
LRCX
+$56.4M
4
AMAT icon
Applied Materials
AMAT
+$51.3M
5
SNDK
Sandisk
SNDK
+$31.8M

Sector Composition

Rank Sector Weight
1 Industrials 34.7%
2 Healthcare 18.78%
3 Technology 12.11%
4 Communication Services 8.47%
5 Utilities 6.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
151
Cogent Biosciences
COGT
$6.03B
$1.35M 0.05%
35,000
– –
LMRI
152
Lumexa Imaging Holdings
LMRI
$1.17B
$1.24M 0.05%
110,000
– –
YSS
153
York Space Systems
YSS
$1.23B
$1.23M 0.05%
50,000
-100,000
-67% -$3.1M
BIOA
154
BioAge Labs
BIOA
$440M
$1.23M 0.05%
50,000
– –
EVMN
155
Evommune Inc
EVMN
$445M
$1.2M 0.05%
90,568
-74,102
-45% -$1.72M
COAG
156
Hemab Therapeutics
COAG
$2.07B
$1.1M 0.04%
+30,000
New +$828K
GLUE icon
157
Monte Rosa Therapeutics
GLUE
$1.18B
$1.09M 0.04%
45,000
– –
LIFE
158
Ethos Technologies Inc
LIFE
$2.54B
$1.09M 0.04%
60,000
– –
SUJA
159
Suja Life Inc
SUJA
$250M
$1.02M 0.04%
+100,000
New +$1.34M
ODTX
160
Odyssey Therapeutics
ODTX
$1.38B
$936K 0.04%
+50,000
New +$877K
VRDN icon
161
Viridian Therapeutics
VRDN
$2.6B
$919K 0.04%
+50,000
New +$806K
IVA
162
Inventiva
IVA
$1.13B
$851K 0.03%
+225,000
New +$1.08M
BRCB
163
Black Rock Coffee Bar Inc
BRCB
$213M
$829K 0.03%
100,000
– –
AKTS
164
Aktis Oncology
AKTS
$1.5B
$806K 0.03%
25,000
– –
DYN icon
165
Dyne Therapeutics
DYN
$4.53B
$777K 0.03%
35,000
– –
CRVS icon
166
Corvus Pharmaceuticals
CRVS
$1.21B
$747K 0.03%
50,000
– –
STM icon
167
STMicroelectronics
STM
$46.6B
$739K 0.03%
+9,869
New +$594K
AGBK
168
AGI Inc
AGBK
$396M
$708K 0.03%
100,000
– –
AGMB
169
AgomAb Therapeutics NV
AGMB
$777M
$618K 0.02%
47,600
-152,400
-76% -$1.72M
CAPR icon
170
Capricor Therapeutics
CAPR
$547M
$602K 0.02%
25,000
-75,000
-75% -$2.27M
NEO icon
171
NeoGenomics
NEO
$2.23B
$515K 0.02%
+35,307
New +$341K
PBLS
172
Parabilis Medicines Inc
PBLS
$4.99B
$274K 0.01%
+10,000
New +$276K
AVR
173
Anteris Technologies
AVR
$881M
$246K 0.01%
25,000
-300,000
-92% -$2.28M
ELOX
174
Eloxx Pharmaceuticals
ELOX
$51.5M
$139K 0.01%
+10,000
New +$128K
INM icon
175
InMed Pharmaceuticals
INM
$7.37M
$38.8K ﹤0.01%
+25,000
New +$27.6K
5 6
7
8 9

Similar funds

SW
SoFi Wealth San Francisco, California $2.48B AUM 22.95% 1-Year Est. Return
SG
SCHF (GPE) Wilson, Wyoming $2.48B AUM 8.43% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
VCM
Valiant Capital Management San Francisco, California $2.48B AUM 57.08% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.49B AUM 10.92% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.48B AUM 21.26% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Seven Grand Managers's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Grand Managers held 249 positions worth $2.48B, up 66% from $1.5B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Seven Grand Managers deployed $863M of net new capital in Q2 2026, opening 82 new positions and adding to 19 existing holdings. Its largest new stake was SpaceX: 1,770,000 shares worth $302M.

By sector, the portfolio is most concentrated in Industrials at 35% of assets, up from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Viper Energy, an estimated $25.4M trimmed.

  • Seven Grand Managers's largest Q2 2026 buy was SpaceX: 1,770,000 shares worth $302M.
  • Seven Grand Managers added most to Medline Inc in Q2 2026, an estimated $46.4M increase.
  • Seven Grand Managers's biggest Q2 2026 reduction was Viper Energy, cutting an estimated $25.4M.
  • Seven Grand Managers fully exited EchoStar in Q2 2026, selling an estimated $81.9M.
  • Seven Grand Managers's ten largest holdings make up 42% of its $2.48B portfolio in Q2 2026.
  • Seven Grand Managers opened 82 new positions and closed 73 in Q2 2026.
  • Seven Grand Managers's portfolio value rose 66% quarter-over-quarter to $2.48B.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.